Navigation Links
Dmitry Medvedev Presented BIOCAD the First National "Industry" Award
Date:7/10/2014

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ --

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD. The Company is developing a unique project called MabNext. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune diseases. The ceremony took place at the International Exhibition "Innoprom 2014" in Ekaterinburg.

     (Logo: http://photos.prnewswire.com/prnh/20140514/686712)

     (Photo: http://photos.prnewswire.com/prnh/20140710/696843 )

According to the Russian Ministry of Health, in the last 12 years the number of new cases of malignant tumors has increased by 11%. The steady increase in the number of cancer patients is a global trend. According to the International Agency for Research on Cancer, in the next 20 years the number of new oncology patients in the world will reach the figure of 22 million cases per year.  Therefore, Russia and the rest of the world are so desperately in need of new effective drugs that will help to overcome serious illnesses and save millions of lives.

BIOCAD is developing a wide portfolio of innovative products based on monoclonal antibodies for treatment of diseases such as breast cancer, colorectal cancer, lung cancer, melanoma, multiple sclerosis, rheumatoid arthritis and psoriasis.

"Now the country is undergoing fundamental changes regarding availability of modern drugs for its people. Thanks to the support of Ministry of Industry and Trade, Ministry of Health, Ministry of Economic Development, Russian pharmaceutical companies are creating a powerful technologic basis for the production of innovative products and are competing successfully on the global pharmaceutical market. Of course, our foreign colleagues are not happy with this. However, now we can deliver innovative medicines that have no analogues in the world. The project MabNext is a bright example of this," said Dmitriy Morozov, CEO of BIOCAD.

The main advantage of products based on monoclonal antibodies, is that they affect only selected cells or molecules, in other words, these are targeted therapies.  Only relevant targets are neutralized without affecting the healthy cells.

BIOCAD has more than 10 of such innovative products based on monoclonal antibodies at different stages of development. One of the most noticeable ones is an antibody specific for interleukin 17. Clinical trials of this drug will begin in 2014. The drug has no analogues on the market and its characteristics are superior to anti-IL17 antibodies being developed by foreign companies. This product has huge potential when it comes to the treatment of socially significant diseases such as rheumatoid arthritis and psoriasis.

If we talk about cancer - the company is at the stage of developing original products based on monoclonal antibodies against targets such as PD-1, HER3, Ang-2 and others. Antibodies for PD-1 increase ability of patient's immune system to recognize and destroy tumor cells.


'/>"/>
SOURCE BIOCAD
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
11. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Recent studies show that cancer ... for specific cancers, such as breast, prostate, or lung, target vital pathways active ... for advanced prostate cancer. , This therapy limits the production and effectiveness ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics ... secured $2M in funding from an impressive group of investors, including Rev1 Ventures, ... Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering that ...
(Date:8/16/2017)... of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ), ... for the third year in a row. Now in its 36th edition, ... set of quantitative metrics. In addition, BioPoint was also named to the ... Bay State . ... ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art technology which ... offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) ... collection vis a vis their members, under their own brand. Three ... offer. ... ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):